Evidence on the cost-effectiveness of lifelong antiretroviral therapy for prevention of mother-to-child transmission of HIV: implications for resource-limited countries in sub-Saharan Africa

Peslie G. Ngambi, Aubrey C. Kalungia, Michael R. Law, Francis Kalemeera, Ilse Truter, Brian Godman, Derick Munkombwe

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: The 2016 World Health Organization (WHO) consolidated guideline recommends lifelong antiretroviral therapy (ART) for all HIV-infected pregnant and breastfeeding women for preventing mother-to-child HIV transmission (PMTCT). Ambiguity remains about the cost-effectiveness of this strategy in resource-limited developing countries.
Areas Covered: We reviewed model-based studies on the cost-effectiveness of lifelong ART (formerly Option B+) relative to previous WHO guidelines for PMTCT. Our search using PubMed, Medline and Google Scholar for articles on Option B+ resulted in the final inclusion of seven studies published between 2012 and 2016. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist was used to assess the quality of reporting. Outcomes of interest, which included infant infections averted, maternal quality and length of life, and the Incremental Cost Effectiveness Ratio (ICER), were used in comparing cost-effectiveness.
Expert Commentary: Despite most model-based studies favouring lifelong ART (Option B+) in terms of cost-effectiveness in comparison to Options A and B, inclusiveness of the evidence remains weak for generalization largely because setting specificity for providing lifelong ART to all pregnant and breastfeeding women may differ significantly in each setting. Therefore, future cost-effectiveness studies should be robust, setting-specific, and endeavor to assess the willingness and ability to pay of each setting.
LanguageEnglish
Pages459-467
Number of pages9
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume17
Issue number5
Early online date3 Aug 2017
DOIs
Publication statusPublished - 11 Aug 2017

Fingerprint

Africa South of the Sahara
Cost-Benefit Analysis
Mothers
HIV
Breast Feeding
Therapeutics
Pregnant Women
Guidelines
Aptitude
Checklist
PubMed
Developing Countries
Quality of Life
Health
Infection

Keywords

  • cost-effectiveness
  • antiretroviral therapy
  • Option B+
  • modelling
  • mother-to-child transmission
  • implications
  • resource-limited countries
  • HIV

Cite this

@article{38e08cebca4641e880e936467ad30e68,
title = "Evidence on the cost-effectiveness of lifelong antiretroviral therapy for prevention of mother-to-child transmission of HIV: implications for resource-limited countries in sub-Saharan Africa",
abstract = "Introduction: The 2016 World Health Organization (WHO) consolidated guideline recommends lifelong antiretroviral therapy (ART) for all HIV-infected pregnant and breastfeeding women for preventing mother-to-child HIV transmission (PMTCT). Ambiguity remains about the cost-effectiveness of this strategy in resource-limited developing countries. Areas Covered: We reviewed model-based studies on the cost-effectiveness of lifelong ART (formerly Option B+) relative to previous WHO guidelines for PMTCT. Our search using PubMed, Medline and Google Scholar for articles on Option B+ resulted in the final inclusion of seven studies published between 2012 and 2016. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist was used to assess the quality of reporting. Outcomes of interest, which included infant infections averted, maternal quality and length of life, and the Incremental Cost Effectiveness Ratio (ICER), were used in comparing cost-effectiveness. Expert Commentary: Despite most model-based studies favouring lifelong ART (Option B+) in terms of cost-effectiveness in comparison to Options A and B, inclusiveness of the evidence remains weak for generalization largely because setting specificity for providing lifelong ART to all pregnant and breastfeeding women may differ significantly in each setting. Therefore, future cost-effectiveness studies should be robust, setting-specific, and endeavor to assess the willingness and ability to pay of each setting.",
keywords = "cost-effectiveness, antiretroviral therapy, Option B+, modelling, mother-to-child transmission, implications, resource-limited countries, HIV",
author = "Ngambi, {Peslie G.} and Kalungia, {Aubrey C.} and Law, {Michael R.} and Francis Kalemeera and Ilse Truter and Brian Godman and Derick Munkombwe",
year = "2017",
month = "8",
day = "11",
doi = "10.1080/14737167.2017.1364161",
language = "English",
volume = "17",
pages = "459--467",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
number = "5",

}

Evidence on the cost-effectiveness of lifelong antiretroviral therapy for prevention of mother-to-child transmission of HIV : implications for resource-limited countries in sub-Saharan Africa. / Ngambi, Peslie G.; Kalungia, Aubrey C.; Law, Michael R.; Kalemeera, Francis; Truter, Ilse; Godman, Brian; Munkombwe, Derick.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 17, No. 5, 11.08.2017, p. 459-467.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evidence on the cost-effectiveness of lifelong antiretroviral therapy for prevention of mother-to-child transmission of HIV

T2 - Expert Review of Pharmacoeconomics and Outcomes Research

AU - Ngambi, Peslie G.

AU - Kalungia, Aubrey C.

AU - Law, Michael R.

AU - Kalemeera, Francis

AU - Truter, Ilse

AU - Godman, Brian

AU - Munkombwe, Derick

PY - 2017/8/11

Y1 - 2017/8/11

N2 - Introduction: The 2016 World Health Organization (WHO) consolidated guideline recommends lifelong antiretroviral therapy (ART) for all HIV-infected pregnant and breastfeeding women for preventing mother-to-child HIV transmission (PMTCT). Ambiguity remains about the cost-effectiveness of this strategy in resource-limited developing countries. Areas Covered: We reviewed model-based studies on the cost-effectiveness of lifelong ART (formerly Option B+) relative to previous WHO guidelines for PMTCT. Our search using PubMed, Medline and Google Scholar for articles on Option B+ resulted in the final inclusion of seven studies published between 2012 and 2016. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist was used to assess the quality of reporting. Outcomes of interest, which included infant infections averted, maternal quality and length of life, and the Incremental Cost Effectiveness Ratio (ICER), were used in comparing cost-effectiveness. Expert Commentary: Despite most model-based studies favouring lifelong ART (Option B+) in terms of cost-effectiveness in comparison to Options A and B, inclusiveness of the evidence remains weak for generalization largely because setting specificity for providing lifelong ART to all pregnant and breastfeeding women may differ significantly in each setting. Therefore, future cost-effectiveness studies should be robust, setting-specific, and endeavor to assess the willingness and ability to pay of each setting.

AB - Introduction: The 2016 World Health Organization (WHO) consolidated guideline recommends lifelong antiretroviral therapy (ART) for all HIV-infected pregnant and breastfeeding women for preventing mother-to-child HIV transmission (PMTCT). Ambiguity remains about the cost-effectiveness of this strategy in resource-limited developing countries. Areas Covered: We reviewed model-based studies on the cost-effectiveness of lifelong ART (formerly Option B+) relative to previous WHO guidelines for PMTCT. Our search using PubMed, Medline and Google Scholar for articles on Option B+ resulted in the final inclusion of seven studies published between 2012 and 2016. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist was used to assess the quality of reporting. Outcomes of interest, which included infant infections averted, maternal quality and length of life, and the Incremental Cost Effectiveness Ratio (ICER), were used in comparing cost-effectiveness. Expert Commentary: Despite most model-based studies favouring lifelong ART (Option B+) in terms of cost-effectiveness in comparison to Options A and B, inclusiveness of the evidence remains weak for generalization largely because setting specificity for providing lifelong ART to all pregnant and breastfeeding women may differ significantly in each setting. Therefore, future cost-effectiveness studies should be robust, setting-specific, and endeavor to assess the willingness and ability to pay of each setting.

KW - cost-effectiveness

KW - antiretroviral therapy

KW - Option B+

KW - modelling

KW - mother-to-child transmission

KW - implications

KW - resource-limited countries

KW - HIV

UR - http://www.tandfonline.com/doi/abs/10.1080/14737167.2017.1364161

U2 - 10.1080/14737167.2017.1364161

DO - 10.1080/14737167.2017.1364161

M3 - Article

VL - 17

SP - 459

EP - 467

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 5

ER -